Haleos Labs Limited Set to Report Q2 FY27 Results November 11
Key highlights
- Haleos Labs is scheduled to report Q2 FY27 results for the September 2026 quarter on November 11, 2026.
- Standalone revenue was ₹67.83 crore in the June 2026 quarter, down 14.19% year-on-year.
- Consolidated net profit attributable to equity holders was ₹2.65 crore in Q1 FY27, down 58% year-on-year.
- Mahi Drugs received zero USFDA Form 483 observations in an inspection held on September 15-18, 2026.
powered by IRIS

Haleos Labs Limited is scheduled to report Q2 FY27 results for the September 2026 quarter on November 11, 2026, after its Q1 consolidated net profit fell 58% year-on-year to ₹2.65 crore. The result is important because investors will assess whether margins and profitability remained stable after the company reported weaker sales and higher material costs in the preceding quarter.
Know Haleos Labs inside out
Results, valuation, peers and who's buying, in one view.
When will Haleos Labs report its Q2 FY27 results?
Haleos Labs is listed among companies scheduled to announce their September-quarter FY27 financial results on November 11, 2026. The quarter under review covers the period ended September 30, 2026.
However, the available material also notes that no board meeting date had been announced for the September 2026 quarter at the time of that commentary. This creates a distinction between the results-calendar listing and a board-meeting intimation. Investors should rely on the company’s exchange filing for the final announcement and the detailed financial statements.
The result will follow the company’s June 2026 quarter disclosure, referred to as Q1 FY27 in the supplied information. That quarter showed a sequential improvement in standalone profit from the March 2026 quarter, but consolidated profitability remained below the year-earlier level.
What did Haleos Labs report in the June 2026 quarter?
Haleos Labs reported standalone revenue from operations of ₹67.83 crore and standalone net profit of ₹3.24 crore for the quarter ended June 30, 2026. Standalone net sales declined 14.19% year-on-year from ₹79.04 crore, while standalone profit fell 37.22% from ₹5.16 crore.
On a quarter-on-quarter basis, standalone net profit increased 45% from ₹2.23 crore in the preceding quarter. The improvement was attributed to inventory benefits in the supplied report. Standalone EBITDA was ₹10.10 crore, down 14.7% year-on-year from ₹11.84 crore.
At the consolidated level, revenue from operations was ₹72.94 crore and net profit attributable to equity holders was ₹2.65 crore. Consolidated profit was down 58% year-on-year from ₹4.16 crore, with higher material costs and lower operational revenue identified as the reasons in the reported commentary.
Which Q2 FY27 metrics will investors watch most closely?
Investors will primarily watch revenue, material costs, EBITDA and net profit when Haleos Labs releases its September-quarter numbers. These measures will indicate whether the June-quarter sequential recovery in standalone profit was sustained in the following quarter.
Margin performance is another key area. The supplied commentary said operating margin had fallen to 5.54% in March 2026 before recovering to 12.5% in June 2026. As lower revenue had earlier been identified as a reason for pressure on profit margin, the September-quarter filing will provide the next reported measure of cost absorption and operating performance.
The company’s reported earnings history also presents a mixed picture. Another set of supplied first-quarter data showed revenue of ₹73.41 crore, down 11% from the comparable prior-year period, and net income of ₹2.65 crore, down 36%, with profit margin at 3.6% against 5.0% a year earlier. The reported consolidated profit figure of ₹2.65 crore is consistent with the other June-quarter disclosure, while investors should use the final financial statements to assess the reporting basis for each revenue measure.
Got a follow-up? Ask IRIS
What regulatory development occurred before the September-quarter results?
Haleos Labs said that its USFDA-inspected material subsidiary, Mahi Drugs Private Limited, received zero Form 483 observations during an inspection conducted from September 15 to September 18, 2026. The company said this matched the outcome of the subsidiary’s previous inspection in January 2025.
A Form 483 is issued by the US Food and Drug Administration when its investigators observe conditions that may constitute violations during an inspection. The zero-observation outcome is therefore a disclosed regulatory-compliance development, although the supplied information does not quantify any direct financial impact from the inspection result.
For Haleos Labs, the update comes shortly before the scheduled reporting of the September quarter. The Q2 financial release may provide investors with updated information on operations, but no forecast for revenue, profit or margins for the unreported quarter was included in the supplied material.
How does the Q2 result matter to shareholders and operations?
The upcoming result matters to shareholders because Haleos Labs has reported contrasting trends across its standalone and consolidated performance. Standalone profit improved sequentially in the June quarter, while consolidated profit declined sharply from the year-earlier period because of higher material costs and lower operational revenue.
The supplied information also said earnings per share had increased by an average of 30% annually over three years, while the share price had increased by an average of 42% annually over the same period. This comparison is historical and does not establish a future valuation outcome, but it places greater focus on the company’s reported earnings delivery.
Customers, suppliers and employees will also look for indications of continuity in production, costs and quality systems. The reported zero Form 483 observations at Mahi Drugs is relevant to regulatory operations, while the financial statement will be the source for any disclosed changes in revenue, expenses or profitability during the September quarter.
Conclusion
Haleos Labs is scheduled to report its September 2026 quarter results on November 11 after a June quarter in which standalone profit rose sequentially but standalone sales and consolidated profit remained lower than the prior-year levels. The central financial questions are whether revenue stabilised, whether material-cost pressure eased and whether the June recovery in operating margin was maintained.
Investors should watch for the exchange filing containing the final Q2 FY27 standalone and consolidated figures, including revenue, EBITDA, net profit and margin disclosures. The available information does not provide a Q2 forecast, and the final board-meeting or results announcement will resolve the timing discrepancy noted in the supplied reports.


